Christopher Lehmann, MD, an assistant professor of medicine at UChicago Medicine and the lead author of the study, highlighted the increasing threat of antibiotic resistance and its escalating impact. The worsening scenario raises concerns about the ability to perform essential medical procedures such as surgeries, safeguard premature infants, and effectively treat cancer without functional antibiotics.
The study focuses on understanding the human microbiome, particularly the gut microbiome, which appears to have evolved over time to combat drug-resistant bacteria. Lehmann emphasized the urgency of comprehending this natural defense mechanism to address the growing challenge of drug-resistant infections, a particularly pertinent issue for vulnerable populations such as liver transplant patients. The researchers conducted a comprehensive analysis of fecal samples from over 100 liver transplant patients to investigate the potential influence of the microbiome on their susceptibility to drug-resistant infections.
The difference between good and bad microbiomes
Lehmann elucidated the diverse array of microbiome compositions observed across various patients, emphasizing the analogy of a healthy microbiome resembling a thriving rainforest with over a trillion bacterial cells and thousands of unique species. In contrast, certain patients exhibited a severely depleted ecosystem, marked by a reduction to a single bacterial species, often one that is detrimental and drug-resistant. This drastic alteration is likened to the environmental impact of clear-cutting a rainforest and replacing it with a single harmful weed species.
The researchers further uncovered that healthy microbiomes play a crucial role in generating essential metabolites—molecules produced during digestion or other biochemical processes within an organism. Among these metabolites are beneficial short-chain fatty acids, as well as secondary bile acids formed when bacteria modify human bile acids to suit their metabolic needs.
In the context of a diverse microbiome, these metabolic processes contribute to the microbiome’s ability to combat drug-resistant bacteria effectively. Notably, certain bile acids demonstrated high toxicity against bacteria such as vancomycin-resistant Enterococcus (VRE), a type of antibiotic-resistant bacteria commonly associated with infections in patients undergoing surgery, cancer treatment, or intensive care. The findings underscore the intricate interplay between the microbiome’s composition and its metabolic functions in the fight against drug-resistant infections.
Poop: A powerful predictor of health and disease
Subsequently, the research team delved into their dataset to investigate whether a correlation existed between the composition of the microbiome and postoperative infections. Surprisingly, they discovered that the presence of drug-resistant pathogens within the microbiome served as a highly accurate predictor for postoperative infections, akin to the precision expected from a conventional clinical test.
Taking their analysis a step further, the researchers opted for a novel approach. Instead of identifying specific bacterial species through genome sequencing, they focused solely on analyzing the metabolites present in patients’ fecal samples to assess if these molecules maintained the same predictive value. Remarkably, relying solely on metabolites enabled the categorization of patients into two distinct groups: those with healthy microbiomes and those with unhealthy microbiomes. Expanding on this breakthrough, the scientists found that the metabolites alone could predict whether a patient would experience an infection.
Christopher Lehmann emphasized the significance of this development, highlighting the potential for quick clinical applications since metabolomic analysis is notably faster than sequencing. While acknowledging the complexity of the current analytical algorithm, Lehmann stressed the necessity for extensive validation before it could be employed as a diagnostic or predictive tool in clinical settings. Nonetheless, these findings establish a foundation for future investigations that aim to reinforce the link between infection and metabolites in fecal samples, paving the way for potential causal relationships to be explored.
Repairing microbiomes to protect against infectious diseases
Christopher Lehmann outlined the next phase of the research trajectory, emphasizing the potential application of their findings in correcting individuals’ microbiomes. For patients with compromised gut microbiomes—characterized by a single harmful species and a heightened risk of infection—there is a prospect of introducing healthy gut bacteria from external sources. This intervention aims to reinstate the production of beneficial metabolites, including molecules like secondary bile acids known to provide protection against drug-resistant infections.
Highlighting the current landscape of microbiome restoration, Lehmann noted the FDA’s approval of two microbiome restoration products in 2023. Contrary to being a distant prospect, microbiome restoration is already a reality. The University of Chicago’s Biological Sciences Division possesses a biobank housing thousands of analyzed and categorized bacteria based on their genomes and metabolite production. In a strategic move, the university is establishing a Good Manufacturing Practices (GMP)-compliant facility, facilitating the production, filtration, and freeze-drying of key gut bacteria derived from healthy donors. These bacteria will be encapsulated in pharmaceutical-grade capsules for convenient consumption.
Lehmann detailed ongoing efforts to create bacterial cocktails tailored to specific patient needs, aiming to reintroduce missing bacteria and promote the production of essential metabolites. The envisioned outcome is the establishment of a robust microbial community in the gut, theoretically defending against future negative outcomes.
Such microbiome restoration capsules hold promise for patients who have undergone broad-spectrum antibiotic treatment, allowing for the replenishment of healthy gut bacteria that may have been eradicated. Additionally, for individuals at high risk of drug-resistant bacterial infections, supplementing their microbiome with specific metabolites could offer a potential protective measure.
Lehmann underscored the urgency of developing new tools in the battle against multiple drug-resistant bacteria. Understanding, testing, and restoring the microbiome are crucial additions to the arsenal of weapons in the quest for effective strategies against these formidable microbial adversaries.
Resources
- ONLINE NEWS University of Chicago Medical Center. (2023, December 16). Microbiome insights found in poop help predict infections in liver transplant patients. Medical Xpress. [Medical Xpress]
- JOURNAL Lehmann, C. J., Dylla, N. P., Odenwald, M., Nayak, R., Khalid, M., Boissiere, J., … Kacha, A. (2023). Fecal metabolite profiling identifies liver transplant recipients at risk for postoperative infection. Cell Host & Microbe. [Cell Host & Microbe]
Cite this page:
APA 7: TWs Editor. (2023, December 18). Infection Prediction in Liver Transplantation Based on Microbiome Insights from Poop. PerEXP Teamworks. [News Link]
